[go: up one dir, main page]

GB9810423D0 - Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy - Google Patents

Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy

Info

Publication number
GB9810423D0
GB9810423D0 GBGB9810423.5A GB9810423A GB9810423D0 GB 9810423 D0 GB9810423 D0 GB 9810423D0 GB 9810423 A GB9810423 A GB 9810423A GB 9810423 D0 GB9810423 D0 GB 9810423D0
Authority
GB
United Kingdom
Prior art keywords
diathermy
ionizing radiation
therapy
antitumour
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9810423.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to GBGB9810423.5A priority Critical patent/GB9810423D0/en
Publication of GB9810423D0 publication Critical patent/GB9810423D0/en
Priority to PCT/GB1999/001362 priority patent/WO1999060142A2/en
Priority to NZ508671A priority patent/NZ508671A/en
Priority to CA002374248A priority patent/CA2374248A1/en
Priority to AU39375/99A priority patent/AU763714B2/en
Priority to EP99922263A priority patent/EP1078091A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9810423.5A 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy Ceased GB9810423D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9810423.5A GB9810423D0 (en) 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
PCT/GB1999/001362 WO1999060142A2 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy
NZ508671A NZ508671A (en) 1998-05-15 1999-05-17 Gene therapy vectors for sensitising cancer cells and their use in antitumour therapy
CA002374248A CA2374248A1 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy
AU39375/99A AU763714B2 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy
EP99922263A EP1078091A2 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810423.5A GB9810423D0 (en) 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy

Publications (1)

Publication Number Publication Date
GB9810423D0 true GB9810423D0 (en) 1998-07-15

Family

ID=10832095

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9810423.5A Ceased GB9810423D0 (en) 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy

Country Status (6)

Country Link
EP (1) EP1078091A2 (en)
AU (1) AU763714B2 (en)
CA (1) CA2374248A1 (en)
GB (1) GB9810423D0 (en)
NZ (1) NZ508671A (en)
WO (1) WO1999060142A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19947668A1 (en) * 1999-10-04 2001-04-19 Univ Eberhard Karls Tumor-specific vector for gene therapy
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
CA2396149A1 (en) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
US6440713B1 (en) 2001-03-01 2002-08-27 Ultra Biotech Limited Methods and compositions for suppressing growth of pathogenic microbes
US6391617B1 (en) 2001-03-01 2002-05-21 Ultra Biotech Limited Yeast compositions for converting bio-available nitrogen in a culture medium to intracellular nitrogen
US6436695B1 (en) 2001-03-01 2002-08-20 Ultra Biotech Limited Yeast compositions for converting bio-available phosphorus in a culture medium to intracellular phosphorus
US6391619B1 (en) 2001-03-01 2002-05-21 Ultra Biotech Limited Methods and compositions for suppressing growth of algae
US6391618B1 (en) 2001-03-01 2002-05-21 Ultra Biotech Limited Methods and compositions for degrading environmental toxins
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
EP1560842A4 (en) * 2002-05-03 2006-04-19 Univ Texas CORREPRESSOR OF STEROID HORMONES RECEPTOR MTA1S
US6753008B2 (en) 2002-06-28 2004-06-22 Ultra Biotech Limited Dietary supplements beneficial for the liver
US6649383B1 (en) 2002-06-28 2003-11-18 Ultra Biotech Limited Dietary supplements beneficial for the gastrointestinal system
US6759055B2 (en) 2002-06-28 2004-07-06 Ultra Biotech Limited Dietary supplements for improving kidney function
US6756050B2 (en) 2002-06-28 2004-06-29 Ultra Biotech Limited Dietary supplements for improving memory
US6793933B2 (en) 2002-06-28 2004-09-21 Ultra Biotech Limited Dietary supplements for enhancing the immune system
US6660508B1 (en) 2002-06-28 2003-12-09 Ultra Biotech Limited Dietary supplements for treating hyperlipemia
US6709849B2 (en) 2002-06-28 2004-03-23 Ultra Biotech Limited Dietary supplements for regulating male hormone
US7078202B2 (en) 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US6979562B2 (en) 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US7259001B2 (en) 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6964864B2 (en) 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US7297522B2 (en) 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy
US9816077B2 (en) * 2011-08-03 2017-11-14 Ramot At Tel-Aviv University Ltd. Use of integrase for targeted gene expression
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
ES2671004T3 (en) * 2013-03-07 2018-06-04 Baylor College Of Medicine Address to CD138 in cancer
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
CA3157063A1 (en) * 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
US20230134550A1 (en) 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
WO2021195214A1 (en) 2020-03-24 2021-09-30 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
DE19530412A1 (en) * 1995-08-18 1997-02-20 Harald Von Prof Dr Melchner Self-deleting retroviral vectors for gene therapy
WO1997017842A1 (en) * 1995-11-13 1997-05-22 University Of Rochester Production of somatic mosaicism in mammals using a recombinatorial substrate
US6274354B1 (en) * 1996-09-06 2001-08-14 The Trustees Of The University Of Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses

Also Published As

Publication number Publication date
AU763714B2 (en) 2003-07-31
AU3937599A (en) 1999-12-06
WO1999060142A2 (en) 1999-11-25
WO1999060142A3 (en) 2000-07-13
CA2374248A1 (en) 1999-11-25
NZ508671A (en) 2003-05-30
EP1078091A2 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
GB9810423D0 (en) Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
IL115584A0 (en) Viral vectors and their use in gene therapy
ZA979096B (en) Viral and cancer treatment
ZA945012B (en) Viral vectors and their use in gene therapy
ZA949104B (en) Recombinant viruses and their use in gene therapy
ZA98497B (en) Medical article with adhered antimicrobial metal ions and related methods
AP9801175A0 (en) Quinoline and quinoline compounds useful in therapy
GB9721909D0 (en) Gene delivery vectors and their uses
ZA949103B (en) Recombinant viruses and their use in gene therapy
PL347542A1 (en) Therapeutic product and its use
AU1598599A (en) Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
GB9812550D0 (en) Tumour therapy and imaging
EP0863204A4 (en) Human cyclin i and gene encoding the same
EP1099755A4 (en) Novel gene and transformant carrying the same
AU5871898A (en) Microparticles and their use in cancer treatment
IL141524A0 (en) Bifunctional antibodies and their use in targeting anti-tumor agents
GB9721494D0 (en) Abrasive articles and their preparations
AU2351699A (en) The human calcium-sensing receptor in the detection and treatment of cancer
HUP0104954A3 (en) Prv-1 gene and the use thereof
HUP9900045A3 (en) Improved leukaemic blood-based product and their use in therapy
GB9912925D0 (en) Adenoviral vectors encoding interferon and their use in gene therapy
AU3698699A (en) Vectors and viruses used in gene therapy
GB9818018D0 (en) Microparticles and their use in therapy
ZA98793B (en) Microparticles and their use in cancer treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)